EVOLOUCUMAB - NEW HYPOLIDEPHEMIC AGENT FOR CARDIOVASCULAR RISK REDUCTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cardiovascular diseases of atherosclerotic origin make a significant contribution to morbidity and mortality in the Russian Federation. Hypercholesterolemia is the leading risk factor for the development of coronary artery disease. The metabolism of low-density lipoproteins (LDL) depends on the activity of the enzyme - proprotein convertase subtilisin/kexin type 9 (PCSK9). A new class of drugs -monoclonal antibodies - inhibits PCSK9 and leads to a marked decrease in LDL cholesterol. An extensive evidence base characterizes ehvolocumab as a safe and effective hypolipidemic agent, which helps to reduce the high risk of developing cardiovascular complications. The use of evolocoumab in patients with clinically significant atherosclerosis and lack of achievement of the target LDL cholesterol levels despite the maximum tolerated therapy with statins with or without ezetimibe, with familial heterozygous and homozygous hypercholesterolemia, and with statin intolerance is justified.

Full Text

Restricted Access

About the authors

M. V Ezhov

SRI of Clinical Cardiology n.a. A.L. Myasnikov; FSBI “Russian Cardiological Research and Production Complex" of RMH

Email: Marat_Ezhov@mail.ru
MD, Leading Researcher at the Department of Atherosclerosis Problems Moscow

References

  1. Метельская В.А., Шальнова С.А., Деев А.Д., Перова Н.В., Гомыранова Н.В., Литинская О.А., Евстифеева С.Е., Артамонова Г.В., Гатагонова Т.М., Гринштейн Ю.И., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Ильин В.А., Либис Р.А., Минаков А.В., Невзорова В.А., РФ). Проф. медицина. 2016;19(1):15-23.
  2. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lance. 2010;376:1670-81.
  3. Оганов Р Г., Кухарчук В.В., Арутюнов Г.П. и др. от имени исследователей DYSIS. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в российской федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012;11(4):70-8.
  4. Catapano A.L., Graham I., DeBacker G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S, Landmesser U., Pedersen T.R., Reiner Z., Riccardi G., Taskinen M.R., Tokgozoglu L., Verschuren W.M., Vlachopoulos C., Wood D.A., Zamorano J.L. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2016;37(39):2999-3058.
  5. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., Darius H., Lewis B.S., Ophuis T.O., Jukema J.W., De Ferrari G.M., Ruzyllo W., De[uicca P., Im K., Bohula E.A., Reist C., Wiviott S.D., Tershakovec A.M., Musliner T.A., Braunwald E., Califf R.M.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med. 2015;372(25):2387-97.
  6. Abifadel M., Varret M., Rabès J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003;34(2):154-56.
  7. Cohen J.C., Boerwinkle E., Mosley T.H.Jr., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 2006;354(12):1264-72.
  8. Астракова К.С., Рагино Ю.И., Шахтшнейдер Е.В., Воевода М.И. Пропротеиновая конвертаза субтилизин/кексин типа 9 (PCSK9) -новые возможности гиполипидемической терапии. Кардиология. 2016;56(9): 84-91.
  9. Raal F.J., Stein E.A., Dufour R., Turner T., Civeira F., Burgess L., Langslet G., Scott R., Olsson A.G., Sullivan D., Hovingh G.K., Cariou B., Gouni-Berthold I., Somaratne R., Bridges I., Scott R., Wasserman S.M., Gaudet D.; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebocontrolled trial. Lancet. 2015;385(9965): 331-40.
  10. Nissen S.E., Stroes E., Dent-Acosta R.E., Rosenson R.S., Lehman S.J., Sattar N., Preiss D., Bruckert E., Ceska R., Lepor N., Ballantyne C.M., Gouni-Berthold I., Elliott M., Brennan D.M., Wasserman S.M., Somaratne R., Scott R., Stein E.A.; GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016;315(15):1580-90.
  11. Robinson J.G., Nedergaard B.S., Rogers W.J., Fialkow J., Neute lJ.M., Ramstad D., Somaratne R., Legg J.C., Nelson P., Scott R., Wasserman S.M., Weiss R.; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870-82.
  12. Sabatine M.S., Giugliano R.P., Wiviott S.D., Raal F.J., Blom D.J., Robinson J., Ballantyne C.M., Somaratne R., Legg J., Wasserman S.M., Scott R., Koren M.J., Stein E.A.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015;372(16): 1500-509.
  13. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316 (22): 2373-84.
  14. Koren M.J., Sabatine M.S., Giugliano R.P., et al. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA. Cardiol. 2017;2(6):598-607.
  15. Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N. Engl. J. Med. 2017;376(18):1713-22.
  16. Giugliano R.P., Mach F., Zavitz K., Kurtz C., Schneider J., Wang H., Keech A., Pedersen T.R., Sabatine M.S., Sever P.S., Honarpour N., Wasserman S.M., Ott B.R.; EBBINGHAUS Investigators. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidlowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clin. Cardiol. 2017;40(2):59-65.
  17. Ежов М.В., Сергиенко, И.В., Рожкова Т.В., Кухарчук В.В., Коновалов Г.А., Бажан С.С., Мешков А.Н., Ершова А.И., Гуревич В.С., Константинов В.О., Соколов А.А., Щербакова М.Ю. Леонтьева И.В., Воевода М.И., Шапошник И.И. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии. Атеросклероз и дислипидемии. 2016;4(25):21-9.
  18. Соколов А.А., Александрова О.Ю., Кашталап В.В. и др. Методические рекомендации по организации медицинской помощи больным с наследственными атерогенными нарушениями липидного обмена в субъектах РФ. Атеросклероз и дислипидемии. 2016;4(25):14-20.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies